These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24398947)

  • 1. Multicompany trials adapt to disciplines beyond cancer.
    Mullard A
    Nat Med; 2014 Jan; 20(1):3. PubMed ID: 24398947
    [No Abstract]   [Full Text] [Related]  

  • 2. Charles Hugh-Jones. Interview by Asher Mullard.
    Hugh-Jones C
    Nat Rev Drug Discov; 2013 Dec; 12(12):900. PubMed ID: 24287774
    [No Abstract]   [Full Text] [Related]  

  • 3. The importance of transparency in industry-sponsored multicenter clinical studies.
    White PF
    Anesth Analg; 2007 Dec; 105(6):1861; author reply 1861-2. PubMed ID: 18042896
    [No Abstract]   [Full Text] [Related]  

  • 4. Reflections on early stopping of a clinical trial.
    Armstrong PW; Granger CB
    Am Heart J; 2006 Sep; 152(3):407-9. PubMed ID: 16923403
    [No Abstract]   [Full Text] [Related]  

  • 5. Arguments against precompetitive collaboration.
    Vargas G; Boutouyrie B; Ostrowitzki S; Santarelli L
    Clin Pharmacol Ther; 2010 May; 87(5):527-9. PubMed ID: 20407456
    [No Abstract]   [Full Text] [Related]  

  • 6. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
    Vallance P; Williams P; Dollery C
    Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
    [No Abstract]   [Full Text] [Related]  

  • 7. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.
    Steensma DP
    J Clin Oncol; 2007 Mar; 25(9):1148; author reply 1148-9. PubMed ID: 17369584
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharma pursues novel models for academic collaboration.
    Hughes B
    Nat Rev Drug Discov; 2008 Aug; 7(8):631-2. PubMed ID: 18670424
    [No Abstract]   [Full Text] [Related]  

  • 9. Breadth plus depth.
    Nat Struct Biol; 2000 Nov; 7(11):995-6. PubMed ID: 11062547
    [No Abstract]   [Full Text] [Related]  

  • 10. ViroLogic announces agreement with Achillion.
    Pharmacogenomics; 2002 Mar; 3(2):163. PubMed ID: 11981960
    [No Abstract]   [Full Text] [Related]  

  • 11. The bridging function of clinical pharmacology.
    Klotz U
    Eur J Clin Pharmacol; 2007 Sep; 63(9):817-9. PubMed ID: 17634934
    [No Abstract]   [Full Text] [Related]  

  • 12. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
    Perakslis ED; Van Dam J; Szalma S
    Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
    [No Abstract]   [Full Text] [Related]  

  • 13. Genaissance pharmaceuticals, inc.
    Oestreicher P
    Pharmacogenomics; 2002 Mar; 3(2):273-6. PubMed ID: 11972448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
    Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
    Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile - Robert Jackson interviewed by Suzanne Berry.
    Jackson R
    Trends Biotechnol; 2002 Nov; 20(11):485-6. PubMed ID: 12413824
    [No Abstract]   [Full Text] [Related]  

  • 16. Notes from the field: jumpstarting the IRB approval process in multicenter studies.
    Blustein J; Regenstein M; Siegel B; Billings J
    Health Serv Res; 2007 Aug; 42(4):1773-82. PubMed ID: 17610447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deal watch: co-promotion deals: panacea or poison pill?
    Borshell N; Papp T
    Nat Rev Drug Discov; 2010 Nov; 9(11):831. PubMed ID: 21030991
    [No Abstract]   [Full Text] [Related]  

  • 19. Algeta and Ablynx collaborate to discover and develop targeted cancer therapies.
    King G
    Future Med Chem; 2013 Feb; 5(2):123. PubMed ID: 23476969
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic success via targeted approaches and strategic partnerships with clinical laboratories.
    Miller GA
    IDrugs; 2007 Mar; 10(3):181-4. PubMed ID: 17351872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.